Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Total Current Liabilities (2016 - 2026)

Pharma-Bio Serv's Total Current Liabilities history spans 16 years, with the latest figure at $3.3 million for Q1 2026.

  • For Q1 2026, Total Current Liabilities fell 3.24% year-over-year to $3.3 million; the TTM value through Jan 2026 reached $3.3 million, down 3.24%, while the annual FY2025 figure was $1.7 million, 7.86% down from the prior year.
  • Total Current Liabilities reached $3.3 million in Q1 2026 per PBSV's latest filing, up from $1.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $3.7 million in Q1 2024 to a low of $1.7 million in Q3 2025.
  • Average Total Current Liabilities over 5 years is $2.3 million, with a median of $2.2 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: plummeted 58.05% in 2022, then soared 87.53% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $2.1 million in 2022, then rose by 2.18% to $2.2 million in 2023, then fell by 12.37% to $1.9 million in 2024, then fell by 7.86% to $1.7 million in 2025, then soared by 90.34% to $3.3 million in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Total Current Liabilities are $3.3 million (Q1 2026), $1.7 million (Q4 2025), and $1.7 million (Q3 2025).